Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14431 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Niuniu Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Hepatopulmonary Syndrome, Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Hypertension, Portal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen High-level Hospital Construction Fund.
Abstract (Originalsprache)
Pulmonary arterial hypertension-targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48-year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2), cTNI, and NT-proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
- Washington University in St. Louis, St. Louis, USA.
Förderung
- Shenzhen High-level Hospital Construction Fund
Zitieren
APA
Li, N., Wu, Q., Meng, J., Feng, C., Jiang, S., Chen, M., Xu, W., Wang, F., Zhang, Y., Liu, J., Xu, C., Liu, G., & Gao, H. (2023). Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review. ESC Heart Failure. https://doi.org/10.1002/ehf2.14431
Vancouver
Li N, Wu Q, Meng J, Feng C, Jiang S, Chen M, et al. Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review. ESC Heart Failure. 2023. doi:10.1002/ehf2.14431
BibTeX
@article{Li2023,
author = {Li, Niuniu and Wu, Qiang and Meng, Juan and Feng, Cheng and Jiang, Siwei and Chen, Meixia and Xu, Wenhui and Wang, Fei and Zhang, Yifan and Liu, Juncai and Xu, Cheng and Liu, Gaolin and Gao, Hong},
title = {Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14431}
}
EUVIMED